A glycosyltransferase mutant and its application

By site-directed mutagenesis of rhamnosyltransferase C12RT, its thermal stability and catalytic activity were improved, solving the activity and stability problems in the biosynthesis of new hesperidin and realizing the efficient and low-cost production of new hesperidin.

CN116463311BActive Publication Date: 2026-11-17TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310352060.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-04-04
Publication Date
2026-11-17
Estimated Expiration
2043-04-04

AI Technical Summary

Technical Problem

In existing biological methods for synthesizing novel hesperidin, the poor catalytic activity and insufficient stability of rhamnosyltransferases limit the industrial production of novel hesperidin through biological synthesis.

Method used

By using site-directed mutagenesis, the thermal stability and catalytic activity of rhamnosyltransferase C12RT were improved, and a new biotransformation route for hesperidin was constructed. The mutant was used to catalyze the conversion of hesperidin-7-O-glucose to the new hesperidin.

Benefits of technology

The synthesis of novel hesperidin was achieved at a high efficiency and low cost. The mutant significantly improved catalytic efficiency and stability, simplified the production process, and enhanced the practical application potential of the biosynthesis of novel hesperidin.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention belongs to the fields of biotechnology and food additives, specifically relating to a rhamnosyltransferase mutant with enhanced catalytic activity and stability, and its applications. Specifically, site-directed mutagenesis improves the thermostability of rhamnosyltransferase C12RT and its resistance to hesperidin-7- O The catalytic activity of glucose was demonstrated, and a biotransformation method for neohesperidin was constructed, successfully achieving the synthesis of neohesperidin from hesperidin, thus overcoming the shortcomings of current biological methods for neohesperidin synthesis. Therefore, the hesperidin synthesis route provided by this invention uses hesperidin as a raw material, converting it to neohesperidin under the continuous catalysis of multiple enzymes. This eliminates the need for the additional addition of expensive UDP-rhamnose, resulting in low cost, a simple process, and high conversion efficiency. It can serve as an alternative to traditional methods for extracting neohesperidin and further enhances the practical application potential of this enzyme in the preparation of important flavonoid glycosides.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the fields of biotechnology and food additives, specifically relating to a rhamnosyltransferase mutant with enhanced catalytic activity and stability and its application. Background Technology

[0002] Neohesperidin is a dihydroflavonoid compound found in plants of the Rutaceae and Rubiaceae families (Yu Hongwei, Zhang Shaoyan, Lu Min, et al. Research progress on neohesperidin [J]. Henan Agricultural Sciences, 2011(08):33-35.). This compound has a variety of biological activities, such as scavenging free radicals, anti-allergy, anti-cancer, lowering blood lipids, and protecting the nervous system. It is also a key intermediate in the synthesis of the important low-calorie sweetener neohesperidin dihydrochalcone (2000 times sweeter than sucrose) (Manthey JA, Grohmann K, Guthrie N. Biological properties of citrus flavonoids pertaining to cancer and inflammation.[J]. Current medicinal chemistry,2001(2):8;[1] Lindley MG, Beyts PK, Canales I, et al. Flavor Modifying Characteristics of the Intense Sweetener NeohesperidinDihydrochalcone[J]. Journal of Food Science,2010,58(3):592-594.). Due to its important physiological functions, neohesperidin is widely used in the biopharmaceutical, food and animal feed industries.

[0003] There are three main methods for preparing neohesperidin reported in the research: 1. Plant extraction, which is mainly extracted from plants of the Rutaceae family such as sour orange, sweet orange, bitter orange, and Rubiaceae family (Uncaria rhynchophylla). This is the most important method for preparing neohesperidin, but the content of neohesperidin in natural plants is low and the extraction rate is low; 2. Chemical synthesis, which uses readily available naringin as raw material for conversion, but the process involves catalysts such as acids and bases; 3. Bioconversion, which uses abundant naringin as raw material and uses glycoside hydrolase and glycosyltransferase to biosynthesize neohesperidin. This method has important economic value, but there are still many problems to be solved before industrial production (Yu Hongwei, Zhang Shaoyan, Lu Min, et al. Research progress of neohesperidin [J]. Henan Agricultural Sciences, 2011(08):33-35.).

[0004] To address the issues of poor catalytic activity and insufficient stability of rhamnosyltransferases in the biosynthesis of neohesperidin, this patent provides a series of rhamnosyltransferase mutants with improved enzyme stability and better catalytic activity, and constructs a complete biosynthetic route for the synthesis of neohesperidin from hesperidin. The process involves: glycoside hydrolase catalyzing the specific formation of the intermediate hesperidin-7-O-glucose from hesperidin, followed by rhamnosyltransferase catalyzing the formation of neohesperidin from this intermediate. Summary of the Invention

[0005] This invention improves the thermostability of rhamnosyltransferase C12RT and its catalytic activity toward hesperidin-7-O-glucose through site-directed mutagenesis; and constructs a biotransformation method for novel hesperidin, successfully realizing the synthesis of novel hesperidin from the conversion of hesperidin, thus overcoming the shortcomings of current biological methods for synthesizing novel hesperidin.

[0006] Therefore, the present invention first provides a glycosyltransferase mutant, which, relative to the amino acid sequence shown in SEQ ID No. 2, has mutations at one or more of the following sites: K35N, K35F, Q49S, Q49T, N58Y, N58D, N58K, Q69H, Q69Y, Q69P, S79P, S79H, Q80D, Q80E, Q80S, D135N, S168D, S168R, S168E, D172E, N179L, N179F, N179A, N179V, Y1 80Q, Y180N, S216A, S216Q, P223S, P223Q, P223K, F242D, F242H, F242Y, K243Y, K243S, Q255K, Q255 P, A314Q, A314K, A314E, Q327L, Q327A, Q327S, Y370N, Y370D, Y370S, S438D, S438Q, N423K, N423Q.

[0007] Preferably, relative to the amino acid sequence shown in SEQ ID No. 2, only the following mutations exist: Y370D / N423K, Y370D / P223Q, Y370D / N179A, Y370D / Q80E, Y370D / Q69P, Y370D / S79P, P223Q / S79P, P223Q / D172E, P223Q / Y180Q, P223Q / S216A, P223Q / Q255K, P223Q / A314L, P223Q / S438E, N179L / P223Q, N179L / K35R, N179L / Q48T, N179L / Q69Y, N179L / D135N, N179L / S168R Models: Q80E / Q327A, Q80E / Q255K, Q80E / N423K, Q80E / A314K, Q80E / A314L, Q80E / S438E; or Y370D / N423K / Q255K, Y370D / N423K / A314E, Y370D / N423K / S438D, P223Q / S438E / K35R, P223Q / S438E / Q80E, P223Q / S438E / S216A, P223Q / S438E / N423K, N179L / Q48T / Y370D, N179L / Q48T / S438D, N179L / Q48T / K35R , Q80E / N423K / Y370D, Q80E / N423K / Q48T, Q80E / N423K / Q69H, Y370D / N423 K / S438D / N179L, Y370D / N423K / S438D / Q80E, P223Q / S438E / S216A / K35R, P 223Q / S438E / S216A / Q255K, N179L / Q48T / Y370D / N423K, Q80E / N423K / Y37 0D / Q48T, Y370D / N423K / S438D / N179L / Q48T, Y370D / N423K / S438D / N179L / N58Y, Y370D / N423K / S438D / N179L / Q80E, Y370D / N423K / S438D / N179L / S1 68R, Y370D / N423K / S438D / N179L / N179A, P223Q / S438E / S216A / Q255K / S79 P, P223Q / S438E / S216A / Q255K / Q80E, P223Q / S438E / S216A / Q255K / D135G , P223Q / S438E / S216A / Q255K / D172E, P223Q / S438E / S216A / Q255K / Y180Q,P223Q / S438E / S216A / Q255K / A314L, P223Q / S438E / S216A / Q255K / N423K , P223Q / S438E / S216A / Q255K / K35R, Q80E / N423K / Y370D / Q48T / Q255K, Q8 0E / N423K / Y370D / Q48T / Q327A, P223Q / S438E / S216A / Q255K / N423K / K35R , P223Q / S438E / S216A / Q255K / N423K / D135G, P223Q / S438E / S216A / Q255K / N423K / D172E, P223Q / S438E / S216A / Q255K / N423K / Y180Q, P223Q / S438 E / S216A / Q255K / N423K / A314L, Y370D / N423K / S438D / N179L / Q48T / Q80E, Y370D / N423K / S438D / N179L / Q48T / Q255K, Y370D / N423K / S438D / N179L / Q 48T / Q80E / Q255K, Y370D / N423K / S438D / N179L / Q48T / Q80E / Q255K / K35R. ,

[0008] Furthermore, the present invention provides the coding gene of the mutant. Preferably, its nucleotide sequence is obtained by mutation based on the nucleotide sequence shown in SEQ ID No. 1.

[0009] The present invention also provides an expression vector for the encoded gene and a host cell.

[0010] The present invention further provides the application of the mutant or its encoding gene or the recombinant host cell in the catalytic synthesis of novel hesperidin.

[0011] Furthermore, this invention provides a method for synthesizing a new hesperidin, which uses hesperidin-7-O-glucose and UDP-rhamnose as substrates, and the mutant as a catalyst to catalyze the reaction to generate a new hesperidin;

[0012] Alternatively, using hesperidin as a substrate, a catalytic reaction is first carried out with rhamnosidase as a catalyst, and then the mutant and UDP-rhamnosyl synthase are added to further catalyze the reaction to obtain a new hesperidin. Preferably, the reaction is carried out at 45-55°C for 10-60 minutes in a reaction system consisting of the substrate hesperidin, rhamnosidase, and Tris-HCl buffer. After enzyme inactivation, the mutant and UDP-rhamnosyl synthase are added and the reaction is carried out at 35-40°C for 1-3 hours.

[0013] Preferably, the catalytic reaction is carried out using whole cells as catalysts.

[0014] More preferably, the catalytic reaction is as follows: 10 mg of hesperidin and 5% glucose are added to the whole cell lysate expressing rhamnosinase, and the reaction is carried out at 45-55°C for 2-12 hours; then, the whole cell lysate expressing the mutant and UDP-rhamnosin synthase is added to the above reaction solution, and the temperature is adjusted to 35-40°C to continue the reaction for 24-72 hours.

[0015] The present invention also provides a strain that co-expresses a novel hesperidin enzyme, wherein the strain is infused with both the coding gene of the mutant and the UDP-rhamnose synthase RHM gene, and preferably the strain is Escherichia coli.

[0016] This invention provides mutation sites that affect the stability and catalytic activity of rhamnosyltransferase C12RT; at the same time, this invention provides a new synthetic route for hesperidin, which uses hesperidin as a raw material and converts it into neohesperidin under the continuous catalysis of multiple enzymes. It does not require the addition of expensive UDP-rhamnose, is low in cost, simple in process, and has high conversion efficiency. It can be used as an alternative to the traditional method for extracting neohesperidin and further enhances the practical application potential of this enzyme in the preparation of important flavonoid glycosides. Attached Figure Description

[0017] Figure 1 SDS-PAGE image of rhamnosyltransferase. Where M: Marker; 1: purified C12RT.

[0018] Figure 2 Liquid phase diagram of the mutant catalyzing the formation of new hesperidin from hesperidin-7-O-glucose.

[0019] Figure 3 Mass spectrum of the mutant catalyzing the formation of a new hesperidin from hesperidin-7-O-glucose. Detailed Implementation

[0020] The present invention will be further described below through specific embodiments to better understand the present invention, but this does not constitute a limitation on the present invention.

[0021] Example 1. Induced expression and activity evaluation of rhamnosyltransferase

[0022] To obtain rhamnosyltransferase, the wild-type rhamnosyltransferase C12RT (nucleotide sequence as shown in SEQ ID NO:1, amino acid sequence as shown in SEQ ID NO:2) and mutant genes were ligated into the pET32a vector and transformed into *E. coli* expression strain BL21(DE3). *E. coli* was inoculated into LB liquid medium containing 100 mg / mL ampicillin and cultured overnight at 37°C and 200 rpm to obtain a seed culture. A 1% inoculum was then inoculated into 50 mL of fresh LB medium and cultured at 37°C and 200 rpm for approximately 3 hours. When OD... 600 When the pH reached approximately 0.7, isopropyl β-D-1-thiogalactopyranose (IPTG) was added to the culture medium to a final concentration of 0.2 mM, and induction was performed at 16°C and 200 rpm for 16 to 24 hours. The strain was collected by centrifugation, and the cells were resuspended in Tris-HCl buffer (pH=7), followed by sonication. The supernatant was obtained by centrifugation and purified using Ni column affinity chromatography to obtain the purified wild-type and mutant target proteins.

[0023] Example 2. Detection of rhamnosyltransferase activity

[0024] The enzyme activity assay system for rhamnosyltransferase was as follows: Tris-HCl (pH = 7.0), 0.2 mM hesperidin-7-O-glucose, 1 mM UDP-rhamnose, 100 μg of pure enzyme solution, reacted at 40 °C for 1 hour (wild type) or 5 μg of pure enzyme solution reacted at 40 °C for 15 minutes (mutant). After the glycosylation reaction was completed, an equal volume of methanol was added to terminate the reaction, and the activity was determined by liquid chromatography and mass spectrometry. High-performance liquid chromatography (HPLC) was performed under the following conditions: an Agilent HPLC system 1200, a C18 column, mobile phase: water + 0.1% formic acid (A), acetonitrile + 0.1% formic acid (B), flow rate: 1 mL / min, sample loading volume: 20 μL. Gradient elution conditions: 0–25 min, 25%–85% mobile phase B, UV detection wavelength: 280 nm. Mass spectrometry conditions: positive ion mode, ESI ion source. The results showed that the substrate hesperidin-7-O-glucose eluted at 7.8 min in the liquid phase, while the product neohesperidin eluted at 7.1 min, with a molecular weight of 611.18 [M+H]. + .

[0025] Example 3. Mutant Construction and Activity Assay

[0026] The specific procedures for obtaining the mutants are as follows: Using the recombinant plasmid pET32-C12RT as a template, and with a pair of primers containing the mutation site, full-plasmid PCR amplification was performed using a high-fidelity enzyme to obtain the recombinant plasmid with the specified mutation site. The amplification product was digested with DpnI enzyme at 37°C for 2 hours to degrade the initial template. The digestion product was transformed into E. coli BL21, plated on LB agar plates containing 100 μg / mL ampicillin, and incubated overnight at 37°C. Two to three clones from each mutation site were selected and transferred to liquid culture medium for culture. After confirming the sequence, the target protein was induced and its expression was verified according to the method in Example 1.

[0027] The results showed that mutations at sites N58, D135, S216, P223, Q255, F242, S438, Q80, K35, Q327, N179, Q49, Q69, S168, K243, A314, Y370, N423, S79, D172, and Y180 significantly affected the enzyme's thermostability. Mutants exhibiting improved stability are shown in Table 1, while the wild-type showed a relative stability of 1.

[0028] Table 1

[0029]

[0030]

[0031]

[0032] Example 4. Combinatorial Mutation

[0033] The single mutation sites mentioned above were combined to obtain double mutants with different combinations (Table 2). The mutants with higher relative stability were further combined with other sites in round-by-round mutation (Table 3), and the relative activities were measured. Tables 2 and 3 list the relative activities of double mutant combinations and multi-mutation combinations with improved relative activities, respectively. The relative activity of wild type was 1.

[0034] Table 2

[0035]

[0036] Table 3

[0037]

[0038]

[0039] Example 5. Enzymatic synthesis of neohesperidin

[0040] The 10 mL reaction system included 10 mg of the substrate hesperidin-7-O-glucose, 20 mg of UDP-rhamnose, 0.5 mg of wild-type rhamnosyltransferase C12RT or 0.10 mg of the mutant enzyme M105, and 50 mM Tris-HCl buffer (pH = 8.0). After reacting for 2–48 hours, 200 μL of sample was added to an equal volume of methanol to terminate the reaction, followed by centrifugation, filtration, and HPLC analysis (Example 2). The results showed that hesperidin-7-O-glucose could be specifically converted to neohesperidin, and the catalytic efficiency of the mutant M105 was much higher than that of the wild type. The mutant M105 could almost completely convert the substrate within 3 hours, while the wild type achieved approximately 60% substrate conversion after 48 hours.

[0041] Example 6. Construction of a strain producing neohesperidin with dual-enzyme co-expression and whole-cell transformation of neohesperidin.

[0042] Using the pETDuet plasmid, the wild-type or mutant rhamnosyltransferase C12RT gene (M105) and the UDP-rhamnosyl synthase RHM gene (NCBI accession number: NP_564633.2) were inserted into multiple cloning sites 1 and 2 of the plasmid, respectively, to construct pETDuet-C12RT. WT -RHM and pETDuet-C12RT M105 The expression plasmid containing pETDuet-C12RT was sequenced and verified to be correct before being introduced into *E. coli* BL21. WT Escherichia coli with the -RHM plasmid (named strain 1) containing pETDuet-C12RT M105 E. coli (strain 2) with the -RHM plasmid were induced to express the new hesperidin, and cells were collected. Cells were resuspended in different pH buffers (50 mM acetate-sodium acetate buffer: pH = 5; 50 mM PB buffer: pH = 6.0-8.0; glycine-sodium hydroxide: pH = 8.0-9.0), and 10 mg of hesperidin-7-O-glucose and 5% glucose were added. After reacting at different temperatures (25, 30, 35, 37, 40, 45℃) for 48 hours, HPLC analysis was performed. The results showed that at pH 5, 6, 7, 8, and 9, mutant M105 specifically converted the substrate to new hesperidin, with conversion rates of 40%, 60%, 70%, 80%, and 45%, respectively. At temperatures of 25, 30, 35, 37, 40, and 45℃, the conversion rates were 41%, 62%, 80%, 75%, 58%, and 49%, respectively. The highest conversion rate of 80% was achieved at pH 8.0 and a temperature of 37°C.

[0043] Example 7. Whole-cell transformation of hesperidin to synthesize neohesperidin

[0044] The pET21 plasmid was used to insert rhamnosidase (α-L-rhamnosidase, NCBI: NP_564633.2) into the multiple cloning site to obtain the rhamnosidase expression vector pET21-Rham. After verification by sequencing, the vector was introduced into *E. coli* BL21. The expression of rhamnosidase in the strain (named strain 3) was induced according to the method in Example 1, and the bacterial cells were collected afterward. Simultaneously, the expression of strains 1 and 2 was induced according to the method in Example 1, and the bacterial cells were collected afterward.

[0045] First, a reaction system was constructed to convert hesperidin to the intermediate product hesperidin-7-O-glucose: In a 10 mL reaction system, strain 3 was resuspended in PB buffer (50 mM, pH = 7.0), and 10 mg of hesperidin and 5% glucose were added. The reaction was carried out at 50 °C for 2–12 hours, and samples were taken for HPLC detection. The results showed that the substrate was completely converted to the single product hesperidin-7-O-glucose within 3 hours. Subsequently, strain 1 or strain 2 was added to the above reaction solution, and the temperature was adjusted to 37 °C for another 48 hours. Strains 1 containing wild-type C12RT and those containing mutant C12RT were also tested. M105 The final transformation rates of strain 2 were 50% and 75%, respectively, meaning that the strain containing the mutant was 50% more efficient than the wild type.

[0046] Example 8. Enzymatic conversion of hesperidin to synthesize neohesperidin

[0047] Strains 1, 2, and 3 were induced to express rhamnosyltransferase according to the method in Example 1. After induction, the bacterial cells were collected and disrupted to collect wild-type rhamnosyltransferase and UDP-rhamnosyl synthase; rhamnosyltransferase mutant M105 and UDP-rhamnosyl synthase; and rhamnosylase. A 10 mL reaction system contained 10 mg of hesperidin, 1 mg of rhamnosylase, and 50 mM Tris-HCl buffer (pH = 7.0), and was reacted at 50°C for 30 minutes. After inactivation at high temperature, 10 mg of rhamnosyltransferase and UDP-rhamnosyl synthase were added, and the reaction was carried out at 37°C for 2 hours. The final conversion rates of new hesperidin were 65% (wild-type) and 90% (M105).

Claims

1. A glycosyltransferase mutant, characterized in that, Based on the amino acid sequence shown in SEQ ID No. 2, perform one of the following mutations: Y370N, Y370D, Y370S, Y370D / N423K, Y370D / P223Q, Y370D / N179A, Y370D / Q80E, Y370D / Q69P, Y370D / S79P, Y370D / N423K / Q255K, Y370D / N423K / A314E, Y370D / N423K / S438D, Q80E / N423K / Y370D, Y370D / N423K / S438D / N179L, Y370D / N423K / S438D / Q80E, N179L / Q48T / Y370D / N423K, Q80E / N423K / Y370D / Q48T, Y370D / N423K / S438D / N179L / Q48T, Y370D / N423K / S438D / N179L / N58Y, Y370D / N423K / S438D / N179L / Q80 E. Y370D / N423K / S438D / N179L / S168R, Y370D / N423K / S438D / N179L / N179A, Q80E / N423K / Y370D / Q48T / Q255K, Q 80E / N423K / Y370D / Q48T / Q327A, Y370D / N423K / S438D / N179L / Q48T / Q80E, Y370D / N423K / S438D / N179L / Q48T / Q255K, Y370D / N423K / S438D / N179L / Q48T / Q80E / Q255K, Y370D / N423K / S438D / N179L / Q48T / Q80E / Q255K / K35R.

2. The coding gene of the mutant as described in claim 1.

3. The genetic code of claim 2, wherein, Its nucleotide sequence was obtained by mutation based on the nucleotide acid sequence shown in SEQ ID No.

1.

4. An expression vector containing the coding gene as described in claim 2 or 3.

5. A recombinant host cell containing the expression vector as described in claim 4.

6. The application of the mutant as described in claim 1 or its encoding gene or the recombinant host cell as described in claim 5 in the catalytic synthesis of novel hesperidin using hesperidin-7-O-glucose and UDP-rhamnose as substrates.

7. A method of synthesizing neohesperidin, characterized by, Using hesperidin-7-O-glucose and UDP-rhamnose as substrates and the mutant as described in claim 1 as a catalyst, a new hesperidin is generated by catalytic reaction.

8. A method of synthesizing neohesperidin, characterized by, Using hesperidin-7-O-glucose and UDP-rhamnose as substrates, a new hesperidin was generated by a whole-cell catalyst. The catalytic reaction is as follows: in the solution of hesperetin-7-O-glucose, 5% of glucose is added, and then the whole cell liquid expressing the mutant of claim 1 and the UDP-rhamnose synthase with the NCBI accession number of NP_564633.2 is added, and the reaction is carried out at a temperature of 35-40 ℃ for 24-72 hours.

9. The method of claim 8, wherein, The whole cell is Escherichia coli.

Citation Information

Patent Citations

  • Tobacco cell capable of producing naringin on large scale as well as preparation method and application of tobacco cell

    CN107267461A

  • Application of alpha-L-rhamnosidase derived from bacteria in efficient production of hesperetin-7-O-glucoside

    CN111944865A